Cinnamic Acid,M-Bromo; Trans-3-Bromocinnamic Acid; M-Bromophenylacrylic Acid; Bromocinnamic Acid,3-; Bromocinnamic Acid,3; M-Bromocinnamic Acid; 3-(3-Bromophenyl)Acrylic Acid; 3-Bromo-Cinnamic Acid; (2E)-3-(3-Bromophenyl)-2-Propenoic Acid; 2-Propenoic Acid, 3-(3-Bromophenyl)-

Brief Introduction

This product can be used as flavors and fragrances, pharmaceutical intermediates, etc.

4-[[4-Carboxybutyl-[2-[2-[[4-(2-Phenylethyl)Phenyl]Methoxy]Phenyl]Ethyl]Amino]Methyl]Benzoic Acid

MSDS

CAS:329773-35-5

Molecular Formula:C36H39NO5

Alias

More Information

Qcr-279; Unii-59K0Y58Uad; Cinaciguat (Jan/Inn); Bay 58-2667; Cinaciguat

Brief Introduction

Cinaciguat is a benzoic acid that is 4-(aminomethyl)benzoic acid in which the amino group is substituted by 4-carboxybutyl and 2-(2-{[4-(2-phenylethyl)benzyl]oxy}phenyl)ethyl groups. It is a soluble guanylate cyclase activator, used for the treatment of acute decompensated heart failure. It has a role as a vasodilator agent, a soluble guanylate cyclase activator and an antihypertensive agent. It is a member of benzoic acids, a tertiary amino compound, an aromatic ether and a dicarboxylic acid.

Avanafil

MSDS

CAS:330784-47-9

Molecular Formula:C23H26ClN7O3

Alias

More Information

4-[(3-Chloro-4-Methoxyphenyl)Methylamino]-2-[(2S)-2-(Hydroxymethyl)Pyrrolidin-1-Yl]-N-(Pyrimidin-2-Ylmethyl)Pyrimidine-5-Carboxamide; Stendra; Ta 1790; Ta-1790

Brief Introduction

Avanalfil is a highly selective oral phosphodiesterase 5 inhibitor. Phase I, II and III clinical trials show that compared with other phosphodiesterase 5 inhibitors, avanafil has the characteristics of rapid onset, short duration and less adverse reactions, and has good clinical effect and safety.

Betrixaban

MSDS

CAS:330942-05-7

Molecular Formula:C23H22ClN5O3

Alias

More Information

N-(5-Chloropyridin-2-Yl)-2-(4-(N,N-Dimethylcarbamimidoyl)Benzamido)-5-Methoxybenzamide; Unii-74Rwp7W0J9; Qcr-99; Bevyxxa; N-(5-Chloropyridin-2-Yl)-2-[[4-(N,N-Dimethylcarbamimidoyl)Benzoyl]Amino]-5-Methoxybenzamide; Betrixaban (Usan); Prt054021

Brief Introduction

Betroxibin is a new, selective and effective oral anticoagulant that directly acts on factor Xa. It has the potential to prevent knee postoperative embolism and atrial fibrillation after stroke. At present, it is in phase III clinical trial. The phase III clinical trial around the world mainly evaluates the role of betroxibin in high-risk patients with venous thromboembolism.

Trans-2,3,4-Trimethoxycinnamic Acid

MSDS

CAS:33130-03-9

Molecular Formula:C12H14O5

Alias

More Information

2,3,4-Trimethoxy-Trans-Cinnamic Acid; 3-(2,3,4-Trimethoxyphenyl)Acrylic Acid; 2,3,4-Trimethoxycinnamic Acid; (2E)-3-(2,3,4-Trimethoxyphenyl)-2-Propenoic Acid

Brief Introduction

This product can be used as pharmaceutical raw materials and pharmaceutical intermediates.

Inquiry (

/ 10

)

Clear All